glp-1 long-term risks side effects cancer Overdose increase as demand for injectable weight-loss drugs on the rise, research finds How GLP-1 Medications Boost Weight

#Retatrutide #Obesity #Endocrinology #ClinicalTrials #Diabetes #GLP1 #FutureofMedicine video credits: To view or add a comment, sign in Day 117 of #RISEChallenge | Drug of the Day: Ramipril Drug Name: Ramipril Class: ACE (Angiotensin-Converting Enzyme) Inhibitor Used for: Hypertension (high blood pressure) Heart failure Post-myocardial infarction (after heart attack) To reduce risk of cardiovascular death in high-risk patients Mechanism of Action: Ramipril inhibits the conversion of angiotensin I to angiotensin II a potent vasoconstrictor

And this is not just one center, but its a command center

She noted associated symptoms of nausea, emesis, photophobia, phonophobia, and lightheadedness

77 A meta-analysis of 76 RCTs, involving over 100,000 adults with overweight, obesity, or type 2 diabetes found that GLP-1 RA treatment, compared to placebo or other active comparators, was associated with a modestly elevated risk of cholelithiasis (RR: 1.27, 95% CI 1.10, 1.47), cholecystitis (RR: 1.36, 95% CI 1.14, 1.62), and overall biliary disease (RR: 1.55, 95% CI 1.08, 2.22), corresponding to an absolute increase of approximately 27 events per 10,000 patients per year

Indeed, we now understand that GLP-1 controls inflammation (75), reduces experimental kidney injury (76), and like GLP-2, acts as a potent intestinal growth factor through mechanisms including stimulation of crypt fission (ref